These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 18540369)

  • 21. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome.
    Buchwald B; Ahangari R; Weishaupt A; Toyka KV
    Ann Neurol; 2002 Jun; 51(6):673-80. PubMed ID: 12112071
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravenous immunoglobulin reduces serum tumor necrosis factor alpha in patients with Guillain-Barre syndrome.
    Reuben S; Sumi MG; Mathai A; Nair MD; Radhakrishnan VV
    Neurol India; 2003 Dec; 51(4):487-9. PubMed ID: 14742928
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacoeconomics of therapy for Guillain-Barré syndrome: plasma exchange and intravenous immunoglobulin.
    Tsai CP; Wang KC; Liu CY; Sheng WY; Lee TC
    J Clin Neurosci; 2007 Jul; 14(7):625-9. PubMed ID: 17532498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical presentation and prognosis of childhood Guillain-Barré syndrome.
    Lee JH; Sung IY; Rew IS
    J Paediatr Child Health; 2008; 44(7-8):449-54. PubMed ID: 18557809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Side effects of combined therapy of methylprednisolone and intravenous immunoglobulin in Guillain-Barré syndrome.
    Odaka M; Tatsumoto M; Hoshiyama E; Hirata K; Yuki N
    Eur Neurol; 2005; 53(4):194-6. PubMed ID: 15970631
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [High-dose intravenous immunoglobulins for treatment of optic neuritis in Guillain-Barré syndrome].
    Lüke C; Dohmen C; Dietlein TS; Brunner R; Lüke M; Krieglstein GK
    Klin Monbl Augenheilkd; 2007 Dec; 224(12):932-4. PubMed ID: 18260057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Corticosteroids can help distinguish between Guillain-Barré syndrome and first attack of chronic inflammatory demyelinating neuropathy: an illustrative case report.
    Alexander KJ; Alshubaili AF; Santhamoorthy P; Sharafuddin KM
    Med Princ Pract; 2008; 17(5):422-4. PubMed ID: 18685286
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Classification of pregnancy complicating Guillain-Barré syndrome].
    Gu YW; Lin J; Zhang LX; Liang XM; Fan HG; Zhao L; Wang LJ; Yang L
    Zhonghua Yi Xue Za Zhi; 2019 May; 99(18):1401-1405. PubMed ID: 31137128
    [No Abstract]   [Full Text] [Related]  

  • 29. Serum IgG levels as biomarkers for optimizing IVIg therapy in CIDP.
    van Doorn PA; Kuitwaard K; Jacobs BC
    J Peripher Nerv Syst; 2011 Jun; 16 Suppl 1():38-40. PubMed ID: 21696496
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of methylprednisolone in patients with Guillain-Barré syndrome.
    Susuki K; Yuki N
    Lancet; 2004 Apr; 363(9416):1236-7; author reply 1237-8. PubMed ID: 15081664
    [No Abstract]   [Full Text] [Related]  

  • 31. Effect of methylprednisolone in patients with Guillain-Barré syndrome.
    Rossi G; Locatelli F
    Lancet; 2004 Apr; 363(9416):1237; author reply 1237-8. PubMed ID: 15081665
    [No Abstract]   [Full Text] [Related]  

  • 32. Evolving pattern of Guillain-Barre syndrome in a community hospital in Israel.
    Kushnir M; Klein C; Pollak L; Rabey JM
    Acta Neurol Scand; 2008 May; 117(5):347-50. PubMed ID: 17995988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Electrophysiological subtypes and long term prognosis of Guillain-Barré syndrome].
    Zhang J; Song XJ; Hou HQ; Tan GJ; Bian GY; Li B; Chen LP; Wang L; Guo L
    Zhonghua Yi Xue Za Zhi; 2016 Jul; 96(25):1987-90. PubMed ID: 27470955
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravenous immunoglobulin and Guillain-Barré syndrome.
    Harel M; Shoenfeld Y
    Clin Rev Allergy Immunol; 2005 Dec; 29(3):281-7. PubMed ID: 16391403
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Guillain-Barré syndrome: an update.
    Vucic S; Kiernan MC; Cornblath DR
    J Clin Neurosci; 2009 Jun; 16(6):733-41. PubMed ID: 19356935
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Autoimmune neuropathies: diagnosis, treatment, and recent topics].
    Ueda M; Kusunoki S
    Brain Nerve; 2011 Jun; 63(6):549-55. PubMed ID: 21613658
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Guillain-Barré syndrome in the elderly: clinical, electrophysiological, therapeutic and outcome features.
    França MC; Deus-Silva L; de Castro R; Garibaldi SG; Pfeilsticker BH; Nucci A; Marques JF
    Arq Neuropsiquiatr; 2005 Sep; 63(3B):772-5. PubMed ID: 16258654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Guillain-Barré syndrome: clinical features, immune mechanisms, and therapies].
    Nomura K
    Rinsho Shinkeigaku; 1996 Dec; 36(12):1367-9. PubMed ID: 9128414
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial.
    Gorson KC; Natarajan N; Ropper AH; Weinstein R
    Muscle Nerve; 2007 Jan; 35(1):66-9. PubMed ID: 16967492
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical features and response to treatment in Guillain-Barré syndrome associated with antibodies to GM1b ganglioside.
    Yuki N; Ang CW; Koga M; Jacobs BC; van Doorn PA; Hirata K; van der Meché FG
    Ann Neurol; 2000 Mar; 47(3):314-21. PubMed ID: 10716250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.